Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A

Drug Metabolism and Disposition

Volumn 26, Issue 7, 1998, Pages 631-639

  Voorman, Richard L ^b   Maio, Stephen M ^c   Hauer, Michael J ^c   Sanders, Philip E ^c   Payne, N Ann ^c   Ackland, Mark J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Drug Metabolism Research   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-HIV AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; DOGS; FEMALE; HIV-1; HUMANS; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0031819080     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ackland MJ (1993) Correlation between site specificity and electrophilic frontier values in the metabolic hydroxylation of biphenyl, di-aromatic and CYP2D6 substrates: A molecular modelling study. Xenobiotica 23:1135-1144.
2. Adams WJ, Hosley JD, Sedlock ML, Anstadt RA, Romero DL, Morozowich W, Smith DP and Douglas SL (1996) Pharmacokinetics, oral bioavailability and dose proportionality of the HIV-1 reverse transcriptase inhibitor delavirdine in the male Sprague-Dawley rat. ISSX Proc 10:428.
3. Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Thomas RC, Aristoff PA, Tarpley WG and Reusser F (1994) Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 47:2017-2028.
4. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
5. Bullock P, Pearce R, Draper A, Podval J, Bracken W, Veltman J, Thomas P and Parkinson A (1995) Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab Dispos 23:736-748.
6. Cadle RM, Zenon GJ III, Rodriguez Barradas MC and Hamill RJ (1994) Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 28:191-195.
7. Chang M, Sood VK, Wilson GJ, Kloosterman DA, Sanders PE, Hauer MJ and Fagerness PE (1997) Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab Dispos 25:228-242.
8. Chang TK, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
9. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL and Stetson PL (1997) Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin Pharmacol Ther 61:531-543.
10. Coutts RT, Su P and Baker GB (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 31:177-186.
11. Damani LA, Crooks PA, Shaker MS, Caldwell J, D'Souza J and Smith RL (1982) Species differences in the metabolic C- and N-oxidation, and N-methylation of [14C]pyridine in vivo. Xenobiotica 12:527-534.
12. Declercq E (1994) How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors. AIDS 8:1020-1021.
13. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, Mayers D, Lane J, Aristoff PA, Thomas RC and Tarpley WG (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 37:1127-1131.
14. Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M and Tarpley WG (1993) A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 90:4713-4717.
15. Fleming CM, Branch RA, Wilkinson GR and Guengerich FP (1992) Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 41:975-980.
16. Genin MJ, Poel TJ, Yagi Y, Biles C, Althaus I, Keiser BJ, Kopta LA, Friis JM, Reusser F, Adams WJ, Olmsted RA, Voorman RL, Thomas RC and Romero DL (1996) Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: Structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs. J Med Chem 39:5267-5275.
17. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA and Stern AM (1991) Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 88:6863-6867.
18. Guengerich FP, Muller Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
19. Hochstein LI and Rittenberg SC (1959) The bacterial oxidation of nicotine: II. The isolation of the first oxidative product and its identification as (1)-6-hydroxynicotine. J Biol Chem 234:156-160.
20. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
21. Katritzky AR (1963) Advances in Heterocyclic Chemistry, Vol. 1, p 347. Academic Press, New York.
22. Kohl C and Gescher A (1996) Catalysis of nitro-aci tautomerism of the genotoxicant 2-nitropropane by cytosol from rodent and human liver. Chem Biol Interact 99:219-226.
23. Kohlstaedt LA, Wang J, Friedman JM, Rice PA and Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
24. Kronbach T, Mathys D, Gut J, Catin T and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
25. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
26. Lemoine A, Johann M and Cresteil T (1990) Evidence for the presence of distinct flavin-containing monooxygenases in human tissues. Arch Biochem Biophys 276:336-342.
27. Lhoest G, Maton N and Verbeeck RK (1993) Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. Drug Metab Dispos 21:850-854.
28. Lu A and Levin W (1972) Partial purification of cytochrome P-450 and cytochrome P-448 from rat liver microsomes. Biochem Biophys Res Commun 46:1334-1339.
29. Mitsuya H, Yarchoan R and Broder S (1990) Molecular targets for AIDS therapy. Science 249:1533-1544.
30. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: Evidence for its hemeprotein nature. J Biol Chem 239:2379-2385.
31. Ortiz de Montellano (1989) Cytochrome P450 catalysis: Radical intermediates and dehydrogenation reactions. Trends Pharmacol Sci 10:354-359.
32. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C and Parkinson A (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145-169.
33. Porter WR, Branch RV and Trager WF (1977) A kinetic method for the determination of the multiple forms of microsomal cytochrome P-450. Biochem Pharmacol 26:549-550.
34. Redinbaugh MG and Turley RB (1986) Adaptation of the bicinchoninic acid protein assay for use with microtitre plates and sucrose density gradient fractions. Anal Biochem 153:267-276.
35. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L and Tarpley WG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 88:8806-8810.
36. Rosenberg ZF and Fauci AS (1991) Immunopathogenesis of HIV infection. FASEB J 10:2382-2390.
37. Steele RGD and Torrie JH (1980) Principles and Procedures of Statistics: A Biometrical Approach, 2nd Ed. McGraw-Hill, New York.
38. vanderHoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
39. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
40. Yarchoan R, Mitsuya H, Myers CE and Broder S (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 321:726-738.
41. Yasumori T, Chen L, Nagata K, Yamazoe Y and Kato R (1993) Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther 264:89-94.